地特胰岛素联合瑞格列奈治疗新诊断2型糖尿病患者的效果及对血尿酸的影响

Influence of Insulin Determir combined with Repaglinide therapy on serum uric acid of newly diagnosed type 2 diabetic patients

目的观察地特胰岛素联合瑞格列奈治疗对新诊断2型糖尿病(T2DM)患者的效果及对血尿酸(UA)水平的影响。方法选择2016年1~6月于我院就诊的新诊断的糖化血红蛋白(Hb A1c)≥8.5%的T2DM患者36例,所有患者给予地特胰岛素联合瑞格列奈治疗12周,比较治疗前后血清UA、空腹血糖(FPG)、餐后2 h血糖(2 h PG)、Hb A1c、血脂、体重、空腹胰岛素水平(FINS),计算胰岛素抵抗指数(HOMA-IR)和胰岛素敏感指数(ISI)。结果与治疗前比较,治疗后ISI由(7.02±3.48)显著升至(7.83±3.39)(P<0.05),FPG、2 h PG、UA、TG、Hb A1c、HOMA-IR显著降低(P<0.05),体重、FINS无明显变化(P>0.05)。结论地特胰岛素联合瑞格列奈治疗可有效改善新诊断T2DM患者的胰岛素抵抗,降低血UA水平。

[Abstract]Objective To explore the Influence of Insulin Determir combined with Repaglinide therapy on serum uric （UA） acid of newly diagnosed type 2 diabetic patients.Methods A total of 36 newly diagnosed type 2 diabetic patients with HbAlc ≥ 8.5% received Insulin Determir combined with Repaglinide therapy for 12 weeks in our hospital from Ja- nurary to June 2016 were selected.A comparison on UA,fasting plasma glucose （FPG）,2 h postprandial glucose （2 h PG）, HbAlc,blood lipid,body weight,fasting insulin（FINS）,homa-insulin resistance（Homa-IR） and insulin sensitivity index（ISI） were performed before and after the treatment.Results Compared with before treatment,ISI was significantly increased from （7.02±3.48） to （7.83±3.39） （P〈0.05）,UA,FPG,2 h PG,HbAlc,TG,LDL-C and Homa-IR were significantly decreased after the treatment （P〈0.05）,and while body weight and FINS had no statistically significant difference before and after the treatment （P〉0.05）.Conclusion Insulin Determir combined with Repaglinide therapy can effectively improve the in- sulin resistance and decrease level of serum UA in the newly diagnosed type 2 diabetic patients.